Welcome to our dedicated page for Contineum Therapeutics SEC filings (Ticker: CTNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Contineum Therapeutics, Inc. (CTNM) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a Nasdaq-listed clinical-stage biopharmaceutical issuer. Contineum files current reports on Form 8-K to describe material events such as clinical data readouts, financing transactions, shareholder votes and trial design updates, alongside its other periodic SEC reports.
For CTNM, clinical development milestones are a recurring theme in its filings. Form 8-K reports have summarized topline data from the PIPE-307 Phase 2 VISTA trial in relapsing-remitting multiple sclerosis and positive topline data from the PIPE-791 Phase 1b PET trial assessing LPA1 receptor occupancy in healthy volunteers and progressive multiple sclerosis patients. Another 8-K details the design of a 26-week, international, randomized, double-blind, placebo-controlled Phase 2 trial of PIPE-791 in idiopathic pulmonary fibrosis, including its primary efficacy measure based on change in forced vital capacity.
Filings also document capital markets activity. Contineum has reported entering into an underwriting agreement for an upsized public offering of its Class A common stock under a shelf registration statement on Form S-3, as well as prior at-the-market offerings. These disclosures outline the terms of offerings, estimated net proceeds and related exhibits such as underwriting agreements and legal opinions.
Investors can use this page to review CTNM’s governance and shareholder matters, including results of its annual meeting of stockholders reported on Form 8-K, where director elections and auditor ratification votes are recorded. With real-time updates from EDGAR and AI-powered summaries, this filings page helps readers quickly understand the key points in Contineum’s 8-Ks and related exhibits, while still allowing full-text access to the underlying SEC documents for deeper analysis.
Contineum Therapeutics supplements its shelf registration to permit “at the market” sales of up to $100,000,000 of Class A common stock through Leerink Partners under an amended sales agreement. The amendment follows prior Sales Agreement activity: 3,241,110 shares were issued for gross proceeds of approximately $19.6 million as of March 5, 2026.
The prospectus supplement states Leerink Partners will act as sales agent (commission up to 3.0%), sales may occur from time to time at prevailing market prices, and the offering is exclusive of amounts previously sold. Shares outstanding used for illustration: 31,236,787 Class A and 6,083,338 Class B as of December 31, 2025.
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small‑molecule therapies for neuroscience, inflammation and immunology diseases. Its lead wholly owned candidate, PIPE‑791, is an LPA1 receptor antagonist in a global Phase 2 trial for idiopathic pulmonary fibrosis and a Phase 1b study for chronic osteoarthritic and low back pain, with top‑line pain data expected in the second quarter of 2026.
The company’s second key asset, PIPE‑307, a selective M1 receptor antagonist, is partnered with Johnson & Johnson under an exclusive global license that included a $50.0 million upfront payment, potential milestones of about $1.0 billion and tiered royalties. A Phase 2 proof‑of‑concept trial in major depressive disorder is underway, while a Phase 2 trial in relapsing‑remitting multiple sclerosis showed acceptable safety but did not meet primary or secondary efficacy endpoints.
Contineum reports high dependency on PIPE‑791 and PIPE‑307, notes significant expected increases in operating expenses, and may require substantial additional capital. As of February 27, 2026, it had 37,336,036 total shares outstanding, including 32,673,536 Class A and 4,662,500 Class B shares.
Contineum Therapeutics, Inc. reported a fourth-quarter 2025 net loss of $15.2 million, similar to the prior-year quarter, as it continued investing in its pipeline. For the full year 2025, net loss was $59.98 million.
Cash, cash equivalents and marketable securities totaled $262.9 million as of December 31, 2025, and the company believes this is sufficient to fund planned operations through mid-2029. Fourth-quarter research and development expenses were $12.8 million, a 2 percent decrease from 2024, while general and administrative expenses were $4.4 million, an 8 percent increase.
The company initiated patient dosing in PROPEL-IPF, a global Phase 2 trial of PIPE-791 in idiopathic pulmonary fibrosis, and expects topline data from an exploratory PIPE-791 Phase 1b chronic pain trial in the second quarter of 2026. Contineum also highlighted a Phase 2 trial of PIPE-307/JNJ-89495120 in major depressive disorder being conducted by Johnson & Johnson. Separately, it amended its at-the-market Sales Agreement with Leerink Partners, filing a new prospectus supplement for the offer and sale of up to $100,000,000 of Class A common stock, exclusive of amounts previously sold, and agreed not to sell shares under this facility through March 11, 2026.
Contineum Therapeutics, Inc. Chief Scientific Officer Daniel S. Lorrain reported an open-market sale of Class A common stock. He sold 4,170 shares on March 2, 2026 at a weighted average price of $15.0084 per share, in multiple trades between $14.60 and $15.41.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 23, 2025. After this transaction, Lorrain directly holds 151,882 shares of Class A common stock, and an additional 6,842 shares are held indirectly by his spouse.
Contineum Therapeutics CMO and Head of Development Tim Watkins reported option-related share movements. On March 2, 2026, he exercised stock options covering 3,611 shares of Class A common stock at $4.50 per share, increasing his option-related holdings to 249,167 shares. He then sold 3,611 shares of Class A common stock in the open market at a weighted average price of $15.0153 per share, with trades executed between $14.60 and $15.41, leaving no shares from this lot outstanding. These transactions were carried out under a Rule 10b5-1 trading plan adopted on September 23, 2025.
Contineum Therapeutics CEO Carmine N. Stengone reported option exercises and share sales in Contineum Therapeutics, Inc. He exercised stock options for 7,100 shares of Class A common stock at an exercise price of $1.26 per share on February 24 and 25, 2026. On the same dates, he sold a total of 7,100 Class A common shares in open-market transactions at weighted average prices of $16.0195 and $16.0155 per share, with actual prices ranging from $16.00 to $16.15. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on September 23, 2025. After these transactions, he held 14,954 shares of Class A common stock and 120,917 stock options directly.
Contineum Therapeutics’ Chief Scientific Officer Daniel S. Lorrain exercised stock options and sold shares in pre-planned trades. He exercised options covering 8,124 shares of Class A common stock at an exercise price of $1.01 per share, then sold 8,124 shares in open-market transactions at weighted average prices around $16 per share under a Rule 10b5-1 trading plan adopted on September 23, 2025. After these transactions, he directly owned 156,052 shares of Class A common stock, with an additional 6,842 shares held indirectly by his spouse.
Contineum Therapeutics, Inc. Chief Scientific Officer Daniel S. Lorrain reported a small set of stock transactions. On February 19, 2026, he exercised stock options for 100 shares of Class A common stock and acquired those 100 shares at a price of $1.01 per share.
On the same date, he sold 100 shares of Class A common stock at a price of $16.00 per share in an open-market transaction. After these transactions, he held 156,052 shares of Class A common stock directly and 6,842 shares indirectly through his spouse. The filing notes the transactions were made under a Rule 10b5-1 trading plan adopted on September 23, 2025.
RA Capital Management and affiliates reported a significant stake in Contineum Therapeutics, Inc. through a Schedule 13G/A filing. As of December 31, 2025, RA Capital Healthcare Fund, L.P. directly holds 2,179,711 shares of Class A common stock, representing 7.2% of the class.
RA Capital Management, L.P. is investment adviser to the fund and has delegated authority to vote and dispose of these shares. Managers Peter Kolchinsky and Rajeev Shah may be deemed beneficial owners through their control of the adviser. The reporting persons state the securities were not acquired to change or influence control of Contineum.
Janus Henderson Group plc reported a significant ownership stake in Contineum Therapeutics, Inc. Class A common stock. Through its investment adviser subsidiaries managing various client accounts, it may be deemed to beneficially own 2,448,979 shares, representing 7.9% of the class.
The firm reports shared voting and dispositive power over all 2,448,979 shares and no sole voting or dispositive power. The underlying managed portfolios receive all dividends and sale proceeds, including Janus Henderson Biotech Innovation Master Fund Ltd., which alone has rights over more than five percent of the class.
The securities are stated as acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of Contineum Therapeutics.